prader willi glp 1 agonist Obesity in Prader–Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches Weight Loss of Over 100

Description

Kim KH, Lee IS, Park JY, Kim Y, An EJ, Jang HJ

23% on placebo) and 63% experienced a BMI reduction of 10% (vs

Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: Systematic review and meta-analysis

DECLARATIONS Authors contributions Controlled the study design and preparation of the article: Ciancimino G, Pecorella F, Viscardi SM, La Mantia C, Caserta A, Pennisi G, Petta S Participated in planning and drafting the article: Ciancimino G, Pecorella F, Viscardi SM, La Mantia C, Caserta A, Pennisi G, Petta S Approved the final draft of the article: Ciancimino G, Pecorella F, Viscardi SM, La Mantia C, Caserta A, Pennisi G, Petta S Availability of data and materials Not applicable